Adalimumab

Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis in India

Zydus Cadila announced the launch of its biosimilar Adalimumab, following an approval from the Drug Controller General (India). According to a press release, the biosimilar was developed by researchers at the Zydus Research Centre. To be marketed under the brand name Exemptia, it will treat auto immune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and Ankylosing Spondylitis.

Though it is estimated that more than 12 million patients in India suffer from these chronic conditions which progressively deteriorate and lead to lifelong pain and in some cases, even disability, Adalimumab, the fully human anti-TNF alpha monoclonal antibody, was not available to patients in India. It was first approved globally in 2002 and has since then been the most preferred therapy to treat patients suffering from auto immune disorders.

Zydus has also announced that it will offer a dedicated Exemptia Care support programme to patients and caregivers. The programme shall provide important support and information regarding access, adherence, awareness and thereby help patients to appropriately manage their disease.

EP News Bureau – Mumbai

© 2017 Cadila Healthcare Ltd. All Rights Reserved. | CompuBrain